Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jutta Bergler-Klein

Showing results (41-50 of 112) with videos related to

Pageof 12
Sort By:
Biomolecules|December 23, 2023
A CircRNA-miRNA-mRNA Network for Exploring Doxorubicin- and Myocet-Induced Cardiotoxicity in a Translational Porcine ModelJulia Mester-Tonczar, Patrick Einzinger, Ena Hasimbegovic, et al.
Journal of Thrombosis and Thrombolysis|April 30, 2021
Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE studyDragos Vinereanu, Dmitry Napalkov, Jutta Bergler-Klein, et al.
Wiener Klinische Wochenschrift|May 4, 2022
Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of CardiologyJutta Bergler-Klein, Peter P Rainer, Markus Wallner, et al.
International Journal of Cardiology|August 10, 2010
Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcomeBernhard Richter, Marianne Gwechenberger, Ariel Socas, et al.
Urologia Internationalis|February 20, 2025
Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)Bernd J Schmitz-Dräger, Ekkehardt Bismarck, Thomas Ebert, et al.
Cardiovascular Research|July 27, 2019
Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistanceMariann Gyöngyösi, Dominika Lukovic, Katrin Zlabinger, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|February 26, 2024
Risk Profiles and Treatment Patterns in Atrial Fibrillation Patients with Chronic Kidney Disease Receiving or not Receiving Anticoagulation TherapyReinhold Kreutz, Gilbert Deray, Jürgen Floege, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|July 16, 2024
Cardiopulmonary exercise testing in transthyretin amyloid cardiomyopathy patients: a long-term follow-up studyRobin Willixhofer, René Rettl, Christina Kronberger, et al.
Diagnostics (Basel, Switzerland)|December 30, 2025
Feasibility of [<sup>68</sup>Ga]Ga-FAPI PET Molecular Imaging in Atherosclerosis Compared with [<sup>18</sup>F]FDG in Oncological PatientsRaffaella Calabretta, Ebru Atli, Barbara Katharina Geist, et al.
Journal of Molecular and Cellular Cardiology|July 8, 2014
Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiencesNoemi Pavo, Silvia Charwat, Noemi Nyolczas, et al.
Pageof 12

Showing results (41-50 of 112) with videos related to

Sort By:
Pageof 12
Biomolecules|December 23, 2023
A CircRNA-miRNA-mRNA Network for Exploring Doxorubicin- and Myocet-Induced Cardiotoxicity in a Translational Porcine ModelJulia Mester-Tonczar, Patrick Einzinger, Ena Hasimbegovic, et al.
Journal of Thrombosis and Thrombolysis|April 30, 2021
Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE studyDragos Vinereanu, Dmitry Napalkov, Jutta Bergler-Klein, et al.
Wiener Klinische Wochenschrift|May 4, 2022
Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of CardiologyJutta Bergler-Klein, Peter P Rainer, Markus Wallner, et al.
International Journal of Cardiology|August 10, 2010
Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcomeBernhard Richter, Marianne Gwechenberger, Ariel Socas, et al.
Urologia Internationalis|February 20, 2025
Cardiovascular Safety of GnRH Agonist-Based Androgen Deprivation Therapy in a Real-World Setting: Results from a Prospective Cohort Study (LEAN)Bernd J Schmitz-Dräger, Ekkehardt Bismarck, Thomas Ebert, et al.
Cardiovascular Research|July 27, 2019
Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistanceMariann Gyöngyösi, Dominika Lukovic, Katrin Zlabinger, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|February 26, 2024
Risk Profiles and Treatment Patterns in Atrial Fibrillation Patients with Chronic Kidney Disease Receiving or not Receiving Anticoagulation TherapyReinhold Kreutz, Gilbert Deray, Jürgen Floege, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|July 16, 2024
Cardiopulmonary exercise testing in transthyretin amyloid cardiomyopathy patients: a long-term follow-up studyRobin Willixhofer, René Rettl, Christina Kronberger, et al.
Diagnostics (Basel, Switzerland)|December 30, 2025
Feasibility of [<sup>68</sup>Ga]Ga-FAPI PET Molecular Imaging in Atherosclerosis Compared with [<sup>18</sup>F]FDG in Oncological PatientsRaffaella Calabretta, Ebru Atli, Barbara Katharina Geist, et al.
Journal of Molecular and Cellular Cardiology|July 8, 2014
Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiencesNoemi Pavo, Silvia Charwat, Noemi Nyolczas, et al.
Pageof 12